Prostate Disorders Clinical Trials

A listing of Prostate Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 370 clinical trials
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

  • 1 views
  • 04 Oct, 2022
  • 19 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will

prostate adenocarcinoma
gonadotropin releasing hormone
adenocarcinoma
bone scan
bone metastases
  • 3 views
  • 04 Oct, 2022
  • 32 locations
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as …

  • 11 views
  • 04 Oct, 2022
  • 113 locations
  • 17 views
  • 07 Oct, 2022
  • 93 locations
  • 88 views
  • 07 Oct, 2022
  • 328 locations
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post abiraterone setting.

direct bilirubin
neutrophil count
prostate adenocarcinoma
platelet count
adenocarcinoma
  • 0 views
  • 04 Oct, 2022
  • 4 locations
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer

Background Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called

  • 0 views
  • 14 Sep, 2022
  • 1 location
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate

  • 0 views
  • 07 Oct, 2022
  • 21 locations
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

poor response to prior abiraterone defined as: Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: < 12 months duration on abiraterone or failure to

  • 2 views
  • 04 Oct, 2022
  • 15 locations
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

3.75mg (depot) of two brands (Luprodex and Lucrin) administered in subjects with advanced adenocarcinoma of the prostate. Approximately 168 subjects (males )of age above 18 years fulfilling the

  • 11 views
  • 04 Oct, 2022
  • 2 locations